"Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" - NAPOLI Struttura Complessa Oncologia Medica Uro-Ginecologica"
Welcome,         Profile    Billing    Logout  
 0 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McBurnie, Jacqui
ENGOT-EN20, NCT05611931: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
PALEO, NCT06290505: A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: Study

Recruiting
2
54
RoW
Durvalumab, Imfinzi
Australasian Gastro-Intestinal Trials Group
Esophageal Cancer
07/27
07/29
RESOLUTE, NCT05862051: Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Recruiting
2
75
RoW
Local Ablative Therapy, Standard first-line systemic treatment
Australasian Gastro-Intestinal Trials Group, Walter and Eliza Hall Institute of Medical Research, Cancer Council Victoria
Colorectal Cancer, Oligometastatic Disease
06/24
06/25
ANZUP 1903, NCT04918810: Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer

Recruiting
2
28
RoW
Docetaxel intermittent
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Peter MacCallum Cancer Centre, Australia
Castration Resistant Prostatic Cancer
06/26
12/26
BA3071-001, NCT05180799: A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Recruiting
1/2
320
US, RoW
BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta)
BioAtla, Inc.
NSCLC, Melanoma
12/25
06/26
Black, Allison
ICON9, NCT03278717: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Recruiting
3
330
Europe, Canada, RoW
Olaparib, Cediranib
University College, London
Ovarian Cancer
12/23
12/23
ENGOT-EN20, NCT05611931: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
ILLUMINATE, NCT03994393: Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Active, not recruiting
2
100
RoW
Tremelimumab, Durvalumab
University of Sydney, AstraZeneca, Australasian Lung Cancer Trials Group
EGFR Mutant Advanced Non Small Cell Lung Cancer
06/23
01/24
Steer, Christopher
ICON9, NCT03278717: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Recruiting
3
330
Europe, Canada, RoW
Olaparib, Cediranib
University College, London
Ovarian Cancer
12/23
12/23
ENGOT-EN20, NCT05611931: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
MoST-TAP, NCT06003621: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting
2
96
RoW
Tiragolumab, RO7092284, MTIG7192A, RG-6058, Anti-TIGIT, Atezolizumab, Tecentriq, MPDL3280A, RG7446, RO5541267
Omico, Hoffmann-La Roche, The George Institute for Global Health, Australia
Solid Tumor, Adult
05/26
11/28
ACTRN12618000284268p: Use of the electronic Rapid Fitness Assessment in older adults with cancer at an Australian Regional Cancer Centre

Not yet recruiting
N/A
50
 
Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre Trust
Cancer in older adults
 
 
ACTRN12618000284268: Use of the electronic Rapid Fitness Assessment in older adults with cancer at an Australian Regional Cancer Centre

Not yet recruiting
N/A
50
 
Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre Trust
Cancer in older adults
 
 
Webber, Kate
ICON9, NCT03278717: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Recruiting
3
330
Europe, Canada, RoW
Olaparib, Cediranib
University College, London
Ovarian Cancer
12/23
12/23
ENGOT-EN20, NCT05611931: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Active, not recruiting
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
ImmunoGen, Inc.
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24

Download Options